{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:30:01Z","timestamp":1776425401306,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5621-5","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T16:05:52Z","timestamp":1556813152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6940-2487","authenticated-orcid":false,"given":"Yoshifumi","family":"Morita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Kiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Hiraide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Konno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"issue":"6","key":"5621_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5621_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12885-018-4610-4","volume":"18","author":"AM Saad","year":"2018","unstructured":"Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018;18(1):688.","journal-title":"BMC Cancer"},{"issue":"1","key":"5621_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5621_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000319414","volume":"28","author":"GJ Krejs","year":"2010","unstructured":"Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Digestive diseases (Basel, Switzerland). 2010;28(2):355\u20138.","journal-title":"Digestive diseases (Basel, Switzerland)"},{"issue":"Suppl 5","key":"5621_CR5","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56\u201368.","journal-title":"Ann Oncol"},{"issue":"8","key":"5621_CR6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(8):1028\u201361.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"5621_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00000658-200301000-00011","volume":"237","author":"JE Lim","year":"2003","unstructured":"Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237(1):74\u201385.","journal-title":"Ann Surg"},{"key":"5621_CR8","doi-asserted-by":"publisher","unstructured":"Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med. 2019;19(1):149\u201357. \n                    https:\/\/doi.org\/10.1007\/s10238-018-0540-3\n                    \n                  . Epub 2018 Nov 29.","DOI":"10.1007\/s10238-018-0540-3"},{"issue":"7","key":"5621_CR9","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.21873\/anticanres.12692","volume":"38","author":"SL Peterson","year":"2018","unstructured":"Peterson SL, Husnain M, Pollack T, Pimentel A, Loaiza-Bonilla A, Westendorf-Overley C, Ratermann K, Anthony L, Desimone P, Goel G, et al. Neoadjuvant nab-paclitaxel and Gemcitabine in borderline Resectable or locally advanced Unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX. Anticancer Res. 2018;38(7):4035\u20139.","journal-title":"Anticancer Res"},{"issue":"3","key":"5621_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama. 2007;297(3):267\u201377.","journal-title":"Jama"},{"issue":"14","key":"5621_CR11","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zulke C, Fahlke J, Arning MB, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Jama. 2013;310(14):1473\u201381.","journal-title":"Jama"},{"issue":"10041","key":"5621_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet (London, England). 2016;388(10041):248\u201357.","journal-title":"Lancet (London, England)"},{"issue":"10073","key":"5621_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet (London, England). 2017;389(10073):1011\u201324.","journal-title":"Lancet (London, England)"},{"key":"5621_CR14","unstructured":"Edge SB, Cancer AJCo: AJCC cancer staging handbook: from the AJCC cancer staging manual, vol. 2010: Springer New York; 2010."},{"key":"5621_CR15","unstructured":"Health UDo, Services H: Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute 2009, 4(03)."},{"issue":"1","key":"5621_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"5","key":"5621_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.surg.2006.12.013","volume":"141","author":"TM Pawlik","year":"2007","unstructured":"Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141(5):610\u20138.","journal-title":"Surgery"},{"issue":"4","key":"5621_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.surg.2014.12.002","volume":"157","author":"T Fujii","year":"2015","unstructured":"Fujii T, Nakao A, Yamada S, Suenaga M, Hattori M, Takami H, Inokawa Y, Kanda M, Sugimoto H, Nomoto S, et al. Vein resections >3 cm during pancreatectomy are associated with poor 1-year patency rates. Surgery. 2015;157(4):708\u201315.","journal-title":"Surgery"},{"issue":"1","key":"5621_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/01.sla.0000259391.84304.2b","volume":"246","author":"CP Raut","year":"2007","unstructured":"Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52\u201360.","journal-title":"Ann Surg"},{"issue":"9","key":"5621_CR20","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1245\/s10434-010-1033-0","volume":"17","author":"N Kondo","year":"2010","unstructured":"Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Nakashima A, Sakabe R, Shigemoto N, Kato Y, et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2010;17(9):2321\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"5621_CR21","first-page":"4865","volume":"35","author":"S Morinaga","year":"2015","unstructured":"Morinaga S, Murakawa M, Katayama Y, Yamaoku K, Aoyama T, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, et al. Glasgow prognostic score predicts clinical outcomes in patients with pancreatic Cancer undergoing adjuvant gemcitabine monotherapy after curative surgery. Anticancer Res. 2015;35(9):4865\u201370.","journal-title":"Anticancer Res"},{"issue":"6","key":"5621_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00280-014-2601-y","volume":"74","author":"T Aoyama","year":"2014","unstructured":"Aoyama T, Katayama Y, Murakawa M, Asari M, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, et al. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer. Cancer Chemother Pharmacol. 2014;74(6):1235\u201340.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"5621_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","volume":"83","author":"KC Fearon","year":"2006","unstructured":"Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006;83(6):1345\u201350.","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"5621_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/0148607114520992","volume":"39","author":"D Hashimoto","year":"2015","unstructured":"Hashimoto D, Chikamoto A, Ohmuraya M, Abe S, Nakagawa S, Beppu T, Takamori H, Hirota M, Baba H. Impact of postoperative weight loss on survival after resection for pancreatic Cancer. JPEN J Parenter Enteral Nutr. 2015;39(5):598\u2013603.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"6","key":"5621_CR25","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1245\/s10434-012-2776-6","volume":"20","author":"T Aoyama","year":"2013","unstructured":"Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K, Hasegawa S, Cho H, Yukawa N, Oshima T, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2013;20(6):2000\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"5621_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jhbp.320","volume":"23","author":"M Sho","year":"2016","unstructured":"Sho M, Murakami Y, Kawai M, Motoi F, Satoi S, Matsumoto I, Honda G, Uemura K, Yanagimoto H, Kurata M, et al. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. J. Hepatobiliary Pancreat. Sci. 2016;23(3):188\u201397.","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"4","key":"5621_CR27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.surg.2005.06.044","volume":"138","author":"MB Farnell","year":"2005","unstructured":"Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138(4):618\u201328 discussion 628-630.","journal-title":"Surgery"},{"issue":"3","key":"5621_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.surg.2014.06.016","volume":"156","author":"JA Tol","year":"2014","unstructured":"Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andren-Sandberg A, Asbun HJ, Bockhorn M, Buchler MW, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the international study group on pancreatic surgery (ISGPS). Surgery. 2014;156(3):591\u2013600.","journal-title":"Surgery"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5621-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T23:16:19Z","timestamp":1588288579000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5621-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5621"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5621-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approval by the ethical committee of Hamamatsu University School of Medicine (approval number: 15\u2013318). Written consents to participate in this study were substituted for providing a means to opt out in the website () according to the ethics guidelines for clinical studies of the Japanese Ministry of Health, Labour and Welfare (MHLW).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"416"}}